Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ADCT ADC Therapeutics SA
$1.25 -6.72% -0.09
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ADCT stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

ADC Therapeutics SA (ADCT)

Loading

Key Stats

Market cap. 175.8M
Enterprise value 441.2M
Trailing PE -1.1339285543987
Forward PE -0.8993289
PEG Ratio 0.014537545569214
Enterprise to EBITDA -5.631
Enterprise to revenue 5.198
Price to book MRQ -0.86269076599244
Price to sales TTM 2.2208114

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 84.9M
EBITDA -78351248
Diluted EPS TTM -0.46
Total Cash (MRQ) 189.2M
Current ratio (MRQ) 3.054
Operating Cash Flow (TTM) -100518000

ADCT trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ADCT News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.